IPF affects the tissue surrounding the air sacs, or alveoli, in the lungs. This condition develops when lung tissue becomes ...

Pulmonary fibrosis in patients with COVID-19 tends to resolve, while idiopathic pulmonary fibrosis always progresses.

Several years ago, my dad was diagnosed with pulmonary fibrosis. The news was a shock. At 84 years old, Daddy had been ...

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it. And, as University of South Florida pulmonologist Dr. Jose ...

Panelists discuss the potential role of emerging treatments in the progressive pulmonary fibrosis (PPF) landscape if approved ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

Columnist Sam Kirton says that at his age, and as someone with pulmonary fibrosis, he's had much experience dealing with grief.

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

Researchers reveal how targeting HIF2 could transform the treatment of idiopathic pulmonary fibrosis (IPF), offering hope for ...

FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...